Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 4
2010 66
2011 157
2012 166
2013 230
2014 212
2015 186
2016 140
2017 131
2018 106
2019 122
2020 100
2021 58
2022 16
2023 20
2024 17

Search Results

1,450 results

Results by year

Filters applied: . Clear all
Page 1
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H, Brown Z, Burns A, Williams T. Barnes H, et al. Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012621. doi: 10.1002/14651858.CD012621.pub2. Cochrane Database Syst Rev. 2019. PMID: 30701543 Free PMC article.
Phosphodiesterase-5 inhibitors.
Cockrill BA, Waxman AB. Cockrill BA, et al. Handb Exp Pharmacol. 2013;218:229-55. doi: 10.1007/978-3-642-38664-0_10. Handb Exp Pharmacol. 2013. PMID: 24092343 Review.
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
Phosphodiesterase type 5 inhibitors and kidney disease.
Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, Kanbay M. Afsar B, et al. Int Urol Nephrol. 2015 Sep;47(9):1521-8. doi: 10.1007/s11255-015-1071-4. Epub 2015 Aug 5. Int Urol Nephrol. 2015. PMID: 26242375 Review.
1,450 results